Scheiner Zachary 4
4 · LENZ Therapeutics, Inc. · Filed Jun 11, 2025
Insider Transaction Report
Form 4
Scheiner Zachary
Director
Transactions
- Award
Stock Option (right to buy)
2025-06-11+13,500→ 13,500 totalExercise: $30.00Exp: 2035-06-10→ Common Stock (13,500 underlying)
Footnotes (2)
- [F1]Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.